HUTCHMED

HCM · Nasdaq · Hong Kong

Share price · HCM

$13.99+1.35 (+10.68%) 3M

close as of 2026-11-18 · 24h delayed · vol 36K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when HCM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Sep 2026+17.2%
  2. 30 Jul 2026-5.4%
  3. 20 Jul 2026+4.4%
  4. 17 Jul 2026-6.6%
  5. 7 Jul 2026-4.9%
  6. 17 Jun 2026-3.5%
  7. 28 May 2026-4.2%
  8. 21 Apr 2026-5.0%
  9. 11 Mar 2026+4.9%
  10. 2 Feb 2026-2.9%

Share of unusual movement by asset

For each asset, the share of HCM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Savolitinib (Orpathys)
events and moves
209%
Fruquintinib (Fruzaqla / Elunate)
events and moves
94%
Other company news (earnings, financing, releases naming no asset)—38%
Sessions with no dated event—49%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Fruquintinib(Fruzaqla / Elunate)
Approved
VEGFR1/2/3Small molecule
Colorectal CancerRenal Cell CarcinomaEndometrial Cancer
Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer
Savolitinib(Orpathys)
Phase 3
METSmall molecule
Non-Small Cell Lung CancerRenal Cell Carcinoma

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Savolitinib · OrpathysPhase 2Lung Cancer
Est. primary completion 2027-01-18 · NCT05374603 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Savolitinib · OrpathysPhase 3Non-small Cell Lung Cancer
Est. primary completion 2028-05-30 · NCT05009836 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Fruquintinib · Fruzaqla / ElunatePhase 3Advanced Endometrial Cancer
Est. primary completion 2029-01-08 · NCT06584032 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(26)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 October 2026PresentationsavolitinibSANOVO Phase III results at ESMO 2026 (LBA69)
China · HUTCHMED · Source ↗
25 October 2026PresentationsavolitinibSAFFRON primary results at ESMO 2026 Presidential Symposium (LBA6)
Global · HUTCHMED · Source ↗
23 October 2026PresentationsurufatinibSurufatinib extrapulmonary NEC data at ESMO 2026 (2394RO)
China · HUTCHMED · Source ↗
29 September 2026Filing submittedsavolitinibUS NDA submitted for savolitinib plus osimertinib
US, FDA · AstraZeneca · Source ↗
3 September 2026Licensing dealHMPL-A830GSK licenses ex-Greater China rights to HMPL-A830
Global excluding Mainland China, Hong Kong, Macau and Taiwan · HUTCHMED · Source ↗
31 August 2026Topline resultsavolitinibSANOVO China Phase III positive high-level results
China · HUTCHMED · Source ↗
28 August 2026ApprovalfanregratinibChina conditional approval of fanregratinib (ATLED) in FGFR2 intrahepatic cholangiocarcinoma
China, NMPA · HUTCHMED · Source ↗
17 August 2026Topline resultsavolitinibSAFFRON Phase III positive high-level results
Global · HUTCHMED · Source ↗
4 July 2026PresentationfanregratinibFanregratinib pivotal Phase II data at ESMO GI 2026 (343RO)
China · HUTCHMED · Source ↗
11 June 2026PresentationsovleplenibESLIM-02 Phase III data presented at EHA 2026 (S301)
China · HUTCHMED · Source ↗
June 2026ApprovalsavolitinibChina conditional approval of ORPATHYS in MET-amplified gastric cancer
China, NMPA · HUTCHMED · Source ↗
1 June 2026PresentationsavolitinibSavolitinib gastric cancer pivotal Phase II data at ASCO 2026 (abstract 4011)
China · HUTCHMED · Source ↗

The 12 most recent of 26 past events are shown.

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$549M$148M$71M+ $1.3B short-term inv.—-$65M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$630M$212M$154M+ $682M short-term inv.—$0.5M operating cash flowreport ↗
2023-FY$838M$302M$284M+ $603M short-term inv.—$219M operating cash flowreport ↗
2022-FY$426M$387M$313M+ $318M short-term inv.$90M-$269M operating cash flowreport ↗
2021-FY$356M$299M$378M+ $634M short-term inv.$49M-$204M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-05-20Chiu Lorenso · Deputy Chief Financial OfficerOther (see filing) (derivative)5,176——Form 4
2026-05-20Su Wei-guo · director, CEO and CSOOther (see filing) (derivative)132,864——Form 4
2026-05-20Nixon Charles George Rupert · Group General CounselOther (see filing) (derivative)7,445——Form 4
2026-05-20Cheng Chig Fung · director, Acting CEO and CFOOther (see filing) (derivative)30,157——Form 4
2026-05-20Chiu Lorenso · Deputy Chief Financial OfficerOther (see filing) (derivative)8,863——Form 4
2026-05-20Su Wei-guo · director, CEO and CSOOther (see filing) (derivative)75,140——Form 4
2026-05-20Nixon Charles George Rupert · Group General CounselOther (see filing) (derivative)7,644——Form 4
2026-05-20Cheng Chig Fung · director, Acting CEO and CFOOther (see filing) (derivative)26,307——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 53 reporting institutions held 4.3M shares ($63.6M, 2.4% of shares outstanding).

#InstitutionSharesValue
1SCHRODER INVESTMENT MANAGEMENT GROUP1,477,494$22.1M
2Allianz Asset Management GmbH837,475$12.5M
3STATE STREET CORP304,829$4.6M
4AIA Group Ltd291,229$4.4M
5M&G PLC255,468$3.8M
6Amundi232,246$3.5M
7RENAISSANCE TECHNOLOGIES LLC132,062$2.0M
8BNP PARIBAS FINANCIAL MARKETS106,504$1.6M
9Crossmark Global Holdings, Inc.84,963$1.3M
10JANE STREET GROUP, LLC76,514$1.1M
11Tidal Investments LLC67,385$1.0M
12DIMENSIONAL FUND ADVISORS LP55,969$837K
13XY Capital Ltd48,394$724K
14UBS Group AG44,758$670K
15CITADEL ADVISORS LLC30,514$456K